Clinical trial

Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant

NCT00188825

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-05-01

PhasePHASE3

Study timeline

Study start (unknown)2004-05-01Date precision: month

Registry last updated2017-05-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

COPDunresolved

Emphysemaunresolved

Alpha-1 Antitrypsan Deficiencyunresolved

Interventions

placeboOTHER

basiliximabDRUG · verified · RxNorm: basiliximab

Sponsors & collaborators

University Health Network, Torontolead sponsor

Novartiscollaborator

Mapped research locations

TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00188825 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.